SHS-006 / Nanjing Sanhome Pharma - LARVOL DELTA

A Phase II/III Clinical Trial of SH006 Combination Therapy versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma. (ChiCTR) - P2/3 | N=120 | Recruiting | Sponsor: Nanjing Tianyinshan Hospital; Nanjing Tianyinshan Hospital

New P2/3 trial • Hepatocellular Cancer • Oncology • Solid Tumor

A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P2/3 | N=120 | Not yet recruiting | Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd.

New P2/3 trial • Hepatocellular Cancer • Oncology • Solid Tumor

A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=50 | Active, not recruiting | Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd.

New P1 trial • Liver Cancer • Oncology • Solid Tumor